22.30
+5.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tyra Biosciences
From its filings with the US Securities and Exchange Commission
Tyra Biosciences is based in Carlsbad, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TYRA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $119.9m. At that date it held total assets of $282.6m and shareholders' equity of $259.2m.
We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.
Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. Through this approach, we have built a wholly-owned pipeline of oral small molecule product candidates focused on targets that have previously been considered difficult-to-drug.
Alterations in the protein receptor FGFR3 are a validated driver in multiple indications with large market opportunities: urothelial cancers and skeletal dysplasia conditions. In urothelial cancer, uncontrolled activation of FGFR3 on the cell surface stimulates cellular proliferation. In skeletal dysplasia conditions, increased activity of FGFR3 expressed in growth plate chondrocytes (cartilage cells) results in excessive limitation of long bone growth.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Sept 2021
- Employees
- 87
- Website
- tyra.bio ↗
- Head office
- 2656 STATE STREET, CARLSBAD, CA, 92008
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Robert MoreIndependent Chairman of the Board$305,688
- Dr. Todd HarrisPresident, Chief Executive Officer, Treasurer, Director, since 2019$7.6m
- Mr. Alan FuhrmanChief Financial Officer$3.5m
- Mr. Bhavesh AsharChief Operating Officer
- Mr. Daniel BensenChief Discovery Officer$2.7m
- Ms. Heather FauldsChief Regulatory Officer
- Dr. Douglas WarnerChief Medical Officer$4.7m
- Ms. Adele GulfoIndependent Director
- Dr. Gilla KaplanIndependent Director$269,188
- Dr. Melissa MccrackenIndependent Director
- Dr. Susan MoranIndependent Director$546,806
- Dr. S. Michael RothenbergIndependent Director$543,553
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 33
- Environment
- 37
- Social
- 28
- Governance
- 35
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Precision oncology focus on FGFR biology targets large opportunities in cancer treatment.
- SNAP platform enables rapid drug design through molecular snapshots predicting resistance.
- Lead product TYRA-300 targets metastatic urothelial carcinoma with initial focus on bladder cancer.
Weaknesses
- Company employs only 38 full-time employees as of 2021 IPO.
- Limited product pipeline with only two oncology candidates in development.
- Initial focus on FGFR3 inhibitor TYRA-300 for bladder cancer patients.
Opportunities
- Expanding FGFR inhibitor therapies to additional cancer types beyond bladder cancer.
- Growing demand for precision medicine in oncology with genetic targeting.
- Developing TYRA-200 for FGFR2 gene alterations in oncology treatments.
Threats
- Competition from established biotech firms in FGFR inhibitor development.
- Regulatory challenges in approval of new oncology drug candidates.
- Market competition for precision medicine targeting genetic alterations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.